BioTechCircle News®
April, 2003
In this issue:
● This month’s original article: “Strategic Partnering = Strategic Synergy” by Joanne F. Gucwa
● Links to 35 Web articles of interest to the biotech community: technology, markets and business
● Biotech Patent Watch - 110 patents in March
Watch for two new interactive sections starting soon: (1) Your biotech business questions; (2) 3-line “Partners Wanted” announcements. For information on submitting questions or placing a partnering ad, contact Joanne F. Gucwa, editor at jogucwa@techmanage.com.
Links to 35 Web articles in 10 categories:
1) Platform technologies (13 articles)
2) Pharmaceuticals (3 articles)
3) Therapeutic categories (5 articles)
4) Agri-biotech (1 article)
5) Diagnostic tools (1 article)
6) Contract services (5 articles)
7) Strategic relationships (2 articles)
8) Investments/government support (1 article)
9) Organizations (1 article)
10) Technology management (3 articles)
Biotech Patent Watch (110 patents across 8 disciplines)
1) Drugs (13 patents)
2) Chemistry: Molecular Biology and Microbiology (57 patents)
3) Chemistry: Natural Resins or Derivatives (2 patents)
4) Organic Compounds (9 patents)
5) Surgery (1 patent)
6) Data Processing: Database and File Management or Data Structures (1 patent)
7) Multicellular Living Organisms (26 patents)
8) Instrumentation (1 patent)
.
Strategic Partnering = Strategic Synergy
Joanne F. Gucwa
Coupling information technology with biotechnology results in bioinformatics, a discipline that enables the conversion of huge amounts of genomic data into practical pathways for drug discovery...synergy because it produces something that neither technology could accomplish easily by themselves.
So too, forming alliances with strategic partners – partners that can help you reach your business goals – can produce business value that exceeds the value of the individual parties (strategic synergy). Here are just some of the reasons to consider strategic partnering.
ACCESS TO SKILLED PEOPLE
Even the largest companies, such as Pfizer, partner with smaller firms to conduct very targeted R&D. This minimizes the costs and risks of the big company trying to develop a similar level of expertise themselves.
FUNDING
Larger companies support smaller firms by contracting with them to conduct R&D. Sometimes funding comes from financial sources such as venture capitalists, angels or even government or private grants. This funding has numerous advantages for smaller firms, including:
* Skilled job creation and keeping skilled workers
* Increased economic value to the local community
* Generating “intellectual capital” to benefit society
MANAGEMENT AND BUSINESS EXPERTISE
Sometimes larger companies take an equity position in the smaller companies, bringing the smaller entities not only funding, but access to management and other expertise.
INCREASED COMPETITIVENESS
Focusing on core competencies and outsourcing activities that others excel at releases funds for marketing and reduces costs. For example, Roche outsources some of its manufacturing to contractors.
http://www.bpicorp.net/mediacenter/Process%20Firms%20Must%20Deconstruct%20For%20Supply%20Nets.pdf
MARKET ACCESS
Many biotech products are co-developed, with the smaller company often providing R&D and the larger one market access through their well-established sales forces. Others develop co-promotional licensing strategies, such as Amgen and Kirin. (Pg. 27 of pdf file below)
http://www.wws.princeton.edu/cgi-bin/byteserv.prl/~ota/disk1/1991/9110/911007.PDF
Finding a manufacturing partner in a foreign country is another means of accessing a biotech market.
1) PLATFORM TECHNOLOGIES (13 articles)
BIOINFORMATICS
“Bowling Ball 'Bioinformatics' hits Ninepins of Asia Pacific”
Frost & Sullivan Asia Pacific, Pharmalicensing (April 16, 2003)
http://pharmalicensing.com/features/disp/1050503155_3e9d67f350b12?1050510553
“A New Language for Genomics?”
Joe McCool, BioMedNet (March 31, 2003)
http://news.bmn.com/news/story?day=030401&story=2
“New Approach to Gene Expression Analysis”
Martina Habeck, BioMedNet (April 7, 2003)
http://news.bmn.com/news/story?day=030408&story=2
BIOMANUFACTURING
“Industrial Bioprocessing”
Al Hester, Frost.com (April 11, 2003)
“Breaking Ground”
Paula Shadle, BioPharm International (April 1, 2003)
http://www.biopharm-mag.com/biopharm/data/articlestandard/biopharm/
“Benchmarking Biotech”
Michael Kamarck, BioPharm International (April 1, 2003)
http://www.biopharm-mag.com/biopharm/data/articlestandard/biopharm/172003/54514/article.pdf
COMBINATORIAL CHEMISTRY
“The Chemical Side of the Double Helix”
Celia M. Henry, Chemical & Engineering News (March 10, 2003)
http://pubs.acs.org/cen/coverstory/8110/8110dna.html
DRUG DISCOVERY
“Less Haste, More Hits”
Julie Clayton, BioMedNet (March 20, 2003)
“An Integrated Approach to Protein Development”
Richard P. Burlingame, PharmaGenomics (March 1, 2003)
HIGH THROUGHPUT SCREENING
“High (Throughput) Mass”
David Bradley, Modern Drug Discovery (April 1, 2003)
http://pubs.acs.org/subscribe/journals/mdd/v06/i04/pdf/403toolbox.pdf
LAB-ON-A-CHIP/DNA CHIPS/MICROARRAY
“Metastasis Gene May Be Useful for Diagnosis and Treatment of Liver Cancer”
National Cancer Institute (March 16, 2003)
http://www.cancer.gov/newscenter/pressreleases/HCC
“Protein Chemistry Surfaces”
Robert M. Frederickson, Bio-IT World (April 15, 2003
http://www.bio-itworld.com/archive/041503/equipt.html
PROTEOMICS
“Proteomics Research Aids Cancer Diagnosis and Treatment”
National Cancer Institute (April 9, 2003)
http://www.cancer.gov/newscenter/pressreleases/AACRproteomics
2) PHARMACEUTICALS (3 articles)
GENERICS
“Generics Battle Heats Up”
Philippe Bennett, PharmExec.com (April 1, 2003)
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=52996
“Generic Treatment Claims: Do They Hold Water?”
Tamsen Valoir, PharmExec.com (April 1, 2003)
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=53001
INDUSTRY
“In the Eye of the Storm”
Jan J. Malek, PharmExec.com (April 1, 2003)
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=52976
3) THERAPEUTIC CATEGORIES (5 articles)
METABOLISM: OBESITY, DIABETES
“Persisting For Painless Monitoring”
Rae Sita Massie, Pharmalicensing (April 2, 2003)
http://pharmalicensing.com/features/disp/1049327613_3e8b77fdce1ae
NEUROLOGY
“Neuroscientists Have Better Tools On the Brain”
Joe Alper, Bio-IT World (April 15, 2003)
http://www.bio-itworld.com/news/041503_report2345.html
ONCOLOGY
“The Mechanics Of Anti-Tumor Activity Outlined”
Vincent Dollard, Biocompare (April 22, 2003)
http://news.biocompare.com/newsstory.asp?id=10241
“New Gene Linked with Breast Cancer”
Reuters, MSNBC News (April 22, 2003)
http://www.msnbc.com/news/903771.asp?0cv=CB10&cp1=1
OPHTHALMOLOGY
“Gene Found for Blind, Deaf Syndrome in Children”
Keith Mulvihill, Reuters Health Information (April 23, 2003)
http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=2616618
4) AGRI-BIOTECH (1 article)
PHARMACEUTICALS
“Commercial Production of Transgenic Crops Genetically Engineered to Produce Pharmaceuticals”
Lon Crosby, BioPharm International (April 1, 2003)
http://www.biopharm-mag.com/biopharm/data/articlestandard/biopharm/172003/54511/article.pdf
5) DIAGNOSTIC TOOLS (1 article)
MRI
“The Anatomy of Metabolism”
Mark S. Lesney, Modern Drug Discovery (April 1, 2003)
http://pubs.acs.org/subscribe/journals/mdd/v06/i04/pdf/403lesney.pdf
6) CONTRACT SERVICES (5 articles)
BIOMANUFACTURING
“Biomanufacturing Responsibilities”
Sandra Fox, et al., Contract Pharma (March 1, 2003)
http://www.contractpharma.com/March031.htm
“Biotech Manufacturing is Coming of Age”
Uwe Gottschalk, BioProcess International (April 1, 2003)
http://www.newslettersonline.com/user/user.fas/s=695/fp=3/tp=64?T=open_article,534421&P=article
CONTRACT RESEARCH
“Outsourcing Outlook”
Jim Miller, Pharmaceutical Technology (April 1, 2003)
http://www.pharmtech.com/pharmtech/data/articlestandard/pharmtech/152003/52998/article.pdf
“Genomic Services Sector Heats Up”
Malorye Branca, Bio-IT World (April 15, 2003)
http://www.bio-itworld.com/news/041503_report2348.html
SINGLE-SOURCE SERVICES
“One-Stop Shops”
Jim Miller, BioPharm International (March 1, 2003)
http://www.biopharm-mag.com/biopharm/data/articlestandard/biopharm/122003/50825/article.pdf
7) STRATEGIC RELATIONSHIPS (2 articles)
COLLABORATION
“Opportunities and Challenges of a Global Discovery Information Structure”
Patrick Quirk and Roland Ortegon, PharmaGenomics (March 1, 2003)
“A Public/Private Partnership for Dual-Use Antibiotics”
Stan N. Finkelstein et al., PharmaGenomics (March 1, 2003)
8) INVESTMENTS/GOVERNMENT SUPPORT (1 article)
VENTURE
“Nothing Ventured”
Michael Greeley, Bio-IT World (April 15, 2003)
http://www.bio-itworld.com/archive/041503/ventured.html
9) ORGANIZATIONS (1 article)
BIG PHARMA
“Pharmaceutical Sales Forces To Expand 22%, New Study Says”
Biocompare (April 23, 2003)
http://news.biocompare.com/newsstory.asp?id=10258
10) TECHNOLOGY MANAGEMENT (3 articles)
CLINICAL TRIAL DATA COLLECTION
“Clinical Trial Data Integrity”
Jules T. Mitchel, et al., Applied Clinical Trials (March 1, 2003)
DATA INTEGRATION
“Technology Overload”
Mark D. Uehling, Bio-IT World (March 10, 2003)
http://www.bio-itworld.com/archive/031003/overload.html
PATENT/INTELLECTUAL PROPERTY ISSUES
“Who Owns That Gene? AgBiotech and Intellectual Property”
Sheldon Krimsky, AgBiotechBUZZ (March 3, 2003)
http://pewagbiotech.org/buzz/display.php3?StoryID=91
PATENT WATCH - March, 2003
110 U.S. patents involving genes
1) DRUGS (13 patents)
“Equine rhinovirus 1 proteins” – The University of Melbourne (Parkville, AU) – 6,531,136
“Recombinant vaccines against IBDV” – Meristem; Rahan, Shafit – 6,528,063
“Methods of producing and using virulence attenuated poxR mutant bacteria” – Megan Health, Inc. – 6,537,558
“Lentiviral vectors”– Chang; Lung-Ji – 6,531,123
“Vaccina virus comprising cytokine and/or tumor associated antigen genes” – Virogenetics Corporation – 6,537,594
“Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein production” – Transkaryotic Therapies, Inc. – 6,537,542
“In vivo production and delivery of insulinotropin for gene therapy” – Transkaryotic Therapies, Inc. – 6,531,124
“Implantation of HSV-TK retrovirus producer cells to destroy glioma” – The General Hospital Corporation – 6,537,541
“Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling” – The Board of Trustees of the Leland Stanford Junior University – 6,528,052
“Protein with plant protecting properties” – Batchikova; Natalia (Turku, FI), et al. – 6,528,480
“Delivery of polynucleotides by secretory gland expression” – The Regents of the University of California – 6,531,455
“Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors” – Avigen, Inc. – 6,531,456
“Method of treating cancer in patients having a deficiency in p53 tumor suppressor gene” – Health Research Inc. – 6,531,512
2) CHEMISTRY: MOLECULAR BIOLOGY AND MICROBIOLOGY (57 patents)
“Bone marrow cells as a source of neurons for brain and spinal cord repair” – University of South Florida – 6,528,245
“Genes encoding exopolysaccharide production” – E. I. du Pont de Nemours and Company – 6,537,786
“Nucleic acids encoding .alpha.-1,3 fucosyltransferases and expression systems for making and expressing them” – The Govenors of the University of Alberta (Edmonton, CA) – 6,534,298
“Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof” – Applera Corporation – 6,528,294
“Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof” – Applera Corporation – 6,534,299
“Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof” – Applera Corporation – 6,537,788
“6835, a novel human phospholipase C family member and uses thereof” – Millennium Pharmaceuticals, Inc. – 6,534,301
“Esterase genes and uses of the same” – Sumitomo Chemical Company, Limited (Osaka, JP) – 6,537,790
“Endonuclease” – Institute of Physical and Chemical Research (Saitama, JP) – 6,528,296
“Human lysozyme gene, its encoded polypeptide and the method for preparing them” – Institute of Genetics Fudan University (Shanghai, CN) – 6,528,297
“Adenoviral vectors encoding a cytokine and a conditionally lethal gene” – Chiron Corporation – 6,531,307
“Ketoreductase gene and protein from yeast” – Eli Lilly and Company – 6,531,308
“ Invasive bacterial vectors for expressing alphavirus replicons” – International Aids Vaccine Initiative – 6,531,313
“BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth” – Board of Regents, The University of Texas Systems – 6,537,804
“Self-deleting vectors” – Melchner; Harald Von, et al (DE) – 6,537,805
“Polynucleotide encoding hCDS1, a human cell-cycle checkpoint kinase” – Janssen Pharmaceutica (Beerse, BE) – 6,531,312
“Drosophila melanogaster p70S6 kinase” – Novartis AG (Basel, CH) – 6,534,311
“Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof” – Xenerex Biosciences – 6,537,809
“Engraftable human neural stem cells” – The Children's of Medical Center Corporation, et al. – 6,528,306
“Methods for regulating T cell subsets by modulating transcription factor activity” – President and Fellows of Harvard College – 6,537,810
“Cancer control” – Takara Shuzo Co., Ltd. (Kyoto, JP) – 6,528,310
“Evolution of whole cells and organisms by recursive sequence recombination” – Maxygen, Inc – 6,528,311
“Encryption of traits using split gene sequences and engineered genetic elements” – MaxyAg, Inc. – 6,531,316
“Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby” – Selective Genetics, Inc. – 6,537,813
“Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made” – Institut Pasteur (Paris, FR) – 6,528,314
“Method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor” – Aventis Pharma S.A. (Antony Cedex, FR) – 6,528,315
“Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made” – Institut Pasteur (Paris, FR) – 6,528,313
“Methods and compositions for transforming cells” – Massachusetts Institute of Technology – 6,534,314
“Method of altering the expression of csrB to modify the properties of a cell” – University of North Texas, Health Science Center at Fort Worth – 6,537,815
“Yeast transformation cassette” – La Societe Lesaffre et Cie (Paris, FR) – 6,534,315
“Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains” – Virco N.V. (Mechelen, BE) – 6,528,251
“CaESS1: a Candida albicans gene, methods for making and using, and targeting it and its expression products for antifungal applications” – Health Research Incorporated – 6,537,753
“Plant fatty acid desaturase promoters” – Cargill Incorporated – 6,537,750
“Oryzacystatin-I applications and methods” – New Mexico State University Technology Transfer Corporation – 6,534,265
“Method of detecting sulphate-reducing bacteria” – Elf Exploration Production (FR) – 6,531,281
“Association of kinesin with sensitivity to chemotherapeutic drugs” – Board of Trustees of the University of Illinois – 6,537,754
“Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma” – Genset S.A. (FR) – 6,531,279
“Solid phase technique for selectively isolating nucleic acids” – Whitehead Institute for Biomedical Research – 6,534,262
“Human BMP-7 promoter and method for exploring bone-related substance by using the same” – Aventis Pharma S.A. (FR) – 6,534,268
“Myeloid cell leukemia associated gene MCL-1" – Dartmouth College – 6,528,263
“Proteases from gram positive organisms” – Genencor International, Inc. – 6,528,255
“DNA assay for the prediction of autoimmune diabetes” – McGill University (Montreal, CA) – 6,534,272
“Method for the simultaneous monitoring of individual mutants in mixed populations” – Council of Scientific & Industrial Research (IN) – 6,528,257
“Isolated nucleic acid molecules encoding transferase enzymes” – Applera Corporation – 6,537,780
“MurD protein and gene of Staphylococcus aureus” – Merck & Co., Inc. – 6,534,284
“Human porphobilinogen deaminase sequences” – Hemebiotech A/S (Hillerod, DK) – 6,537,777
“Synthetic ligation reassembly in directed evolution” – Diversa Corporation – 6,537,776
“Nuclear tyrosine kinase Rak” – The University of North Carolina at Chapel Hill – 6,531,296
“Gene involved in cadasil, method of diagnosis and therapeutic application” – Institut National de la Sante et de la Recherche (INSERM) (Paris, FR), et al. – 6,537,775
“Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof” – The Institute for Genomic Research, et al. – 6,537,773
“Members of the D52 Gene family” – Institute National de la Sante et de la Recherche Medicale (Paris Cedex, FR), et al. – 6,528,283
“Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof” – Applera Corporation – 6,531,297
“Methods to identify compounds that affect the expression level of the syntaxin-1 A encoding gene” – University of British Columbia (Vancouver, CA) – 6,531,288
“Screening for antibiotics” – Millennium Pharmaceuticals, Inc. – 6,534,278
“Self-regulated apoptosis of inflammatory cells by gene therapy” – Boehringer Ingelheim Pharmaceuticals Inc. – 6,537,784
“Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing” – Cornell Research Foundation, Inc, Sloan-Kettering Institute for Cancer Research – 6,534,293
“Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof” – Human Genome Sciences, Inc., Johns Hopkins University – 6,528,289
3) CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF (2 patents)
“Sid-polyamide fusions: a potent method of regulating gene expression” – University of Utah Research Foundation – 6,528,620
“Compositions and methods relating to DNA mismatch repair genes” – Dana-Farber Cancer Institute, Oregon Health Sciences University – 6,538,108
4) ORGANIC COMPOUNDS (9 patents)
“Genomic sequence of the human .mu.-opioid receptor gene and the variants, polymorphisms and mutations thereof” – Max-Delbruck-Centrum fur Molekulare Medizin (Berlin, DE) – 6,538,120
“Steroid/thyroid hormone receptor-related gene which is inappropriately expressed in human hepatocellular carcinoma and which is a retinoic acid receptor” – Institut Pasteur (Paris, FR) – 6,531,585
“ Compositions and methods for the treatment and diagnosis of cardiovascular disease” – Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital – 6,534,641
“Drosophila recombination-associated protein and methods for use” – Albert Einstein College of Medicine of Yeshiva University – 6,534,643
“Insertion sequence element derived from Ralstonia solanacearum” – National Institute of Agrobiological Sciences (JP) – 6,538,125
“Toxins active against pests” – Mycogen Corporation – 6,534,644
“Promoter sequence of 3-phosphoglycerate kinase gene 2 of lactic acid-producing fungus rhizopus oryzae and a method of expressing a gene of interest in fungal species” – Battelle Memorial Institute – 6,528,636
“Methods for HIV sequencing and genotyping” – Applera Corporation – 6,531,588
“Synthetic ribonucleic acids with RNAse activity” – Ribozyme Pharmaceuticals, incorporated – 6,528,640
5) SURGERY (1 patent)
“Method for chronic catheterization of the common bile duct of a laboratory rat” – Rush-Presbyterian St. Luke's Medical Center 6,537,267
6) DATA PROCESSING: DATABASE AND FILE MANAGEMENT OR DATA STRUCTURES (1 patent)
“Gene expression and evaluation system using a filter table with a gene expression database” – Affymetrix, Inc. – 6,532,462
7) MULTICELLULAR LIVING ORGANISMS AND UNMODIFIED PARTS THEREOF AND RELATED PROCESSES (26 patents)
“Quantitative trait loci associated with soybean cyst nematode resistance and uses thereof” – Pioneer Hi-Bred International, Inc. – 6,538,175
“Strain manipulation and improvement in the edible seaweed Porphyra” – Northeastern University – 6,531,646
“Grain processing method and transgenic plants useful therein” – Syngenta Participations AG (Basel, CH) – 6,531,648
“Targeted manipulation of genes in plants” – Pioneer Hi-Bred International, Inc. – 6,528,700
“Production of transgenic impatiens” – Ball Horticultural Company – 6,528,703
“Plant genes and uses thereof” – Syngenta Participations AG (Basel, CH) – 6,528,702
“Gene silencing methods” – Plant Bioscience Limited (Norfolk, GB) – 6,531,647
“Maize replication protein A and use” – Pioneer Hi-Bred International, Inc. – 6,538,176
“Rice ubiquitin-derived promoters” – Board of Supervisors of Louisiana State University – 6,528,701
“Compositions and methods for fumonisin detoxification” – Pioneer Hi-Bred International, Inc. – 6,538,177
“Glycogen biosynthetic enzymes in plants” – Calgene LLC – 6,538,181
“Enhanced starch biosynthesis in seeds” – Monsanto Technology LLC – 6,538,179
“Method for increasing sucrose content of plants” – Unilever Patent Holdings B.V. (Vlaardingen, NL) – 6,538,180
“Seed-preferred promoters from end genes” – Pioneer Hi-Bred International, Inc. – 6,528,704
“Method for improving productivity of higher plants” – Nara Institute of Science and Technology (Ikoma, JP) – 6,528,705
“Identification and characterization of a Dwarf and Late Flowering 2 phenotype (DLF2) in Arabidopsis” – Agrinomics LLC – 6,534,695
“Polyhydroxybutyrate polymerase” Massachusetts Institute of Technology – 6,528,706
“Method of producing a poppy plant” – Council of Scientific and Industrial Research (New Delhi, IN) – 6,534,696
“DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants” – Senesco, Inc. – 6,538,182
“Methods for identifying anti-cancer drug targets” – Exelixis, Inc. – 6,531,644
“RAS/P21 transgenic mouse” == University of South Florida – 6,531,645
“Transgenic sugar beet plant expressing cp4/epsps enzyme activity” – Syngenta Participations AG (Basel, CH) – 6,531,649
“Impatiens plants and methods of reproduction” – Cosner; Harlan, Cosner; Sue – 6,528,707
“Transgenically produced non-secreted proteins” – Genzyme Transgenics Corporation – 6,528,699
“Compositions and methods for wound healing” – The Wistar Institute – 6,538,173
“Animal model for transplantation” – Fremantle Hospital (Fremantle, AU) – 6,538,174
8) INSTRUMENTATION (1 patent)
“Method of finding, recording and evaluating object structures” – Leica Microsystems Heidelberg GmbH (Heidelberg, DE) – 6,529,271
Copyright 2003, Technology Management Associates, Inc.. All rights reserved. Please do not reprint, e-mail or host on your Web site, without explicit permission. This newsletter is for your use only.